Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four classes of antihypertensive drugs used to manage high blood pressure and related cardiovascular conditions. The combination includes: - **ACE inhibitors** (angiotensin-converting enzyme inhibitors): These block the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. - **Angiotensin receptor blockers (ARBs)**: These block the action of angiotensin II at its receptor, also resulting in vasodilation and lower blood pressure. - **Beta blockers**: These reduce heart rate and cardiac output by blocking beta-adrenergic receptors, thereby lowering blood pressure. - **Calcium channel blockers**: These prevent calcium from entering cardiac and vascular smooth muscle cells, causing relaxation of vessels and reduction in heart workload. Each class has a distinct mechanism but all contribute synergistically to lowering blood pressure. Such multi-drug regimens are often used for patients with resistant hypertension or those who do not achieve target pressures with fewer agents. This combination is not typically available as a single fixed-dose product but may be prescribed as separate medications taken together[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ace inhibitors + angiotensin receptor blockers + beta blockers + calcium channel blockers.